Dr. Reddy's Laboratories has temporarily paused the supply of its generic semaglutide product after flagging an issue with the active pharmaceutical ingredient. The company has not provided further details about the nature of the API problem or a timeline for resumption.
Dr. Reddy's Laboratories has decided to press pause on the supply of its generic semaglutide. The pharmaceutical company took this step after identifying a concern related to the active pharmaceutical ingredient, commonly referred to as API, used in the product. This temporary halt affects the distribution of the generic version of the drug.
A generic semaglutide is a copy of the brand-name drug that uses the same active ingredient. The API is the component of the medication that produces its intended therapeutic effect. In this case, Dr. Reddy's flagged an issue with that API, which prompted the supply interruption.
The decision to pause supply was made by Dr. Reddy's after the API issue was flagged. The company has not elaborated on the specific nature or cause of the API problem. The supply halt is in effect as a result of this flagged concern.
Because Dr. Reddy's has paused supply, its generic semaglutide is currently not available for distribution. The company has not announced when the supply might resume or how long the pause will last. The only information provided is that the pause was triggered by an API issue.
Peptides referenced: Semaglutide.
Related reading: Dr. Reddy's Expects Semaglutide Shortage Through Late October, GLP-1 Drug Use Among US Adults Reaches 11%, Gallup Poll Shows, FDA Approves Second IGF-1R Antibody for Thyroid Eye Disease, Bachem Holding AG Focuses on Peptide Manufacturing Amid Growing Biotech Demand.